Log in to save to my catalogue

Survival Outcomes of Patients with Primary Plasma Cell Leukemia in the Era of Proteasome Inhibitors...

Survival Outcomes of Patients with Primary Plasma Cell Leukemia in the Era of Proteasome Inhibitors...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_6aa61488e7664a47bfbd018ec500c8e1

Survival Outcomes of Patients with Primary Plasma Cell Leukemia in the Era of Proteasome Inhibitors and Immunomodulatory Agents: A Real-Life Multicenter Analysis

Publication information

Publisher

Turkey: Galenos Publishing House

More information

Scope and Contents

Contents

In this study, we aimed to obtain real-life data on the use of antimyeloma agents, which significantly increase overall survival (OS) in multiple myeloma (MM) patients, in primary plasma cell leukemia (pPCL) patients with poor prognosis.
Data from 53 patients who were diagnosed with pPCL between 2011 and 2020 and who used at least one proteasome...

Alternative Titles

Full title

Survival Outcomes of Patients with Primary Plasma Cell Leukemia in the Era of Proteasome Inhibitors and Immunomodulatory Agents: A Real-Life Multicenter Analysis

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_6aa61488e7664a47bfbd018ec500c8e1

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_6aa61488e7664a47bfbd018ec500c8e1

Other Identifiers

ISSN

1300-7777,1308-5263

E-ISSN

1308-5263

DOI

10.4274/tjh.galenos.2024.2023.0450

How to access this item